1.88 USD
↘ 0.44 (18.97%)AT CLOSE (11:59 AM EDT)
GRI Bio, Inc. Common Stock
GRINASDAQ • USD
1.83
↘ 0.05 (2.66%)
POST MARKET (AS OF 07:46 PM EDT)
Post Market
AS OF 07:46 PM EDT
1.83
↘ 0.05 (2.66%)
Market: CLOSED
GRI Bio, Inc. Common Stock (GRI) trades at $1.88 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, GRI appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Jun 18, 2026.
Open?$2.11
High?$2.16
Low?$1.81
Prev. Close?$2.32
Volume?642.8K
Avg. Volume?84.0K
VWAP?$2.13
Rel. Volume?7.65x
Bid / Ask
Bid?$1.81 × 200
Ask?$1.90 × 100
Spread?$0.09
Midpoint?$1.86
Valuation & Ratios
Market Cap?3.3M
Shares Out?1.8M
Float?1.4M
Float %?97.9%
P/E Ratio?N/A
P/B Ratio?0.32
EPS?-$6.16
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Address
2223 AVENIDA DE LA PLAYA
LA JOLLA, CA 92037
Phone: (619) 400-1171
LA JOLLA, CA 92037
Phone: (619) 400-1171
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?55
Piotroski F-Score?0/9Weak
Altman Z-Score?-6.18Distress
Confidence?45%Low
Short InterestElevated
Short % of Float?8.73%Elevated
Short Interest?123.5K
Days to Cover?3.8
Free Float1.4M
Avg Daily Volume32.9K
Settlement Date2026-05-29
Financial Health
Current Ratio?14.21Strong
Quick Ratio?14.21Strong
Cash Ratio?13.91Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.32CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.7CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-103.4%WEAK▾
S&P3
ROA?-96.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-12138000
Enterprise Value?$-7718825
Fundamentals ratios updated end of day